Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2026 ,inter alia, to consider and approve unaudited standalone and consolidated ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supha Pharmachem Ltd has informed BSE that its Board Meeting, originally scheduled for February 14, 2026 and then rescheduled to February 25, 2026, has been further postponed to March 9, 2026. The postponement is due to the non-availability of financial information from its overseas subsidiary in Singapore, which is required to finalise the consolidated financial results. The Board will now consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The trading window for insiders remains closed since January 1, 2026 and will reopen 48 hours after the results are declared.
The repeated delays in announcing Q3 FY26 results, especially due to pending subsidiary financials, may cause short-term uncertainty for shareholders. Investors should monitor for the actual results on March 9, 2026 to assess the company's financial health, particularly the Singapore subsidiary's contribution.